UPDATE: Citi Downgrades Celgene (CELG) to Neutral

(Updated - October 20, 2017 6:42 AM EDT)

(updated to add analyst comment)

Citi downgraded Celgene (NASDAQ: CELG) from Buy to Neutral with a price target of $140.00 (from $157.00).

Analyst Robyn Karnauskas downgrades the stock noting a lack of major catalysts in the NT. Further the analyst believes NT Revlimid and great generic pressures could create overhang without any upside catalysts.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $135.96 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• JPMorgan Downgrades Dassault Systemes SE (DSY:FP) (DASTY) to Neutral
• JPMorgan Upgrades Aker Solutions ASA (AKSO:NO) (AKRTF) to Neutral
• RELX Plc. (REL:LN) (RELX) PT Raised to GBP42 at JPMorgan